Washington to Pause Use of Johnson & Johnson COVID-19 Vaccine

The Washington State Department of Health will pause the use of the Johnson & Johnson (J & J) vaccine statewide starting immediately, following the guidance of the FDA/CDC. Use of that vaccine will be put on hold until we receive further recommendations from our federal partners about how best to move forward. Safety is the highest priority when it comes to all COVID-19 vaccines.

This action is being taken out of an abundance of caution based on the appearance of a rare but serious side effect including serious brain blood clots (CVST) combined with low platelet counts in six patients, all women under 50. The CDC’s Advisory Committee on Immunization Practices (ACIP) will review these cases in the days ahead and will recommend guidance going forward. 

About 149,000 doses of Johnson & Johnson vaccine have been administered in Washington so far, out of more than four million doses total. At this time, we have no knowledge of the six patients who experienced these blood clots being Washington residents.

For those who got the vaccine more than a month ago, the risk of this complication is very low at this time. People who have received the Johnson & Johnson who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider. It also demonstrates how well the robust vaccine safety monitoring systems work, since this potential safety concern was identified quickly and vaccines were paused to allow for further investigation.

No definitive cause has been identified yet, but the FDA said today that a probable cause is a rare immune response generated by an individual after receiving the vaccine.

DOH will continue to monitor the situation related to Johnson & Johnson and update on its use as the pause is reviewed and once it is lifted.

The above is a press release from the WA State Dept of Health.  The Auburn Examiner has not independently verified its contents and encourages our readers to personally verify any information they find may be overly biased or questionable. The publication of this press release does not indicate an endorsement of its content.